<DOC>
	<DOCNO>NCT02341625</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics , immunogenicity , antitumor activity pharmacodynamics BMS-986148 administer alone combination nivolumab patient mesothelioma , non-small cell lung cancer , ovarian cancer , pancreatic cancer gastric cancer .</brief_summary>
	<brief_title>A Study BMS-986148 Patients With Select Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com Must pancreatic , ovarian , gastric , nonsmall cell cancer mesothelioma . For dose expansion , must tumor positive mesothelin Expected life expectancy least 3 month Men woman 18 year old old ( local age majority ) Must measurable tumor per Response Evaluation Criteria In Solid Tumors ( RECIST ) modify RECIST malignant pleural mesothelioma ECOG 0 1 Cancer metastasis brain Moderate eye disorder Active infection past hepatitis B C infection Major surgery less 1 month start study Uncontrolled heart disease Impaired liver bone marrow function History allergy mesothelindirected antibody , tubulysin , monoclonal antibody , nivolumab related compound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>